dwoolfrey

HOUSTON, TX., September 9, 2019 — GREFFEX, INC. won a contract of up to $18.9 million with the National Institute of Health’s National Institute for Allergy and Infectious Diseases to develop and exploit its GreVac(TM) Plug-And-Play Technology to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases to target emerging infectious threats, whether natural or man-made.

GreVac(TM) vaccines are based upon GREFFEX’s proprietary GreGT Genetic Engineering Technology as a fast and flexible plug-and-play vaccine architecture of fully deleted helper virus- independent adenoviral vectors of rare serotypes. The proprietary GreGT platform has been built upon two independently modifiable components to provide broad gene transfer applications.

The GreVac(TM) system incorporates versatility and speed to complement and ultimately change the present paradigm of immune protection against infectious diseases with a high eruption potential from the stockpiling of potential vaccine candidates to the just-in-time production of specific vaccines.

With support by the present NIH contract, GREFFEX expects to advance the development of two of its GreVac(TM) influenza vaccines through clinical trials. The activity of a vaccine directed against a highly pathogenic avian influenza will be compared to a novel universal influenza vaccine. This research initiative is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract HHS-NIH-NIAID-BAA2018 (BAA-2018 Omnibus Broad Agency Announcement: Research Area 2 (DMID) – Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases).

Read the full press release here

Greffex, Inc., a company leading a paradigm shift in the design, development and production of vaccines, elected two new members to its board of directors on Monday. They are John D. White, founder and chairman of PSP Capital and former U.S. Ambassador to Qatar, Chase Untermeyer. Both are accomplished leaders and will bring significant global and national experience to Greffex, Inc.

“John and Chase are both strong leaders with impressive accomplishments and contributions that span across business and public service,” said John R. Price, Co-Chairman of the Board, President and Chief Executive of Greffex, Inc. “They will serve as valuable additions to the board.”

Read the full press release here

Greffex, Inc. and the Texas A&M University System (TAMUS) are excited to announce a collaboration on advanced process and manufacturing development. This agreement will advance the research and development of Greffex vaccines and assist the Health Science Center’s Center for Innovation in Advanced Development and Manufacturing (CIADM) at TAMUS to establish a robust, efficient pipeline of countermeasures to public health emergencies both in the US and worldwide.

From the press release:

“As we prepare for the next phase of research and development, we needed a creative, innovative “university-based” partner to assist us in our long-range development plans,” said John R. Price, President and CEO of Greffex, “and in Texas A&M Health Science Center’s Center for Innovation in Advanced Development and Manufacturing (CIADM), we found the creative, forward-thinking researchers who can leverage the resources of the entire university system.”

Read the full press release here